Samsung and Bayer invest $90M in Berlin-based digital health tech startup Ada Health to become the Alexa of healthcare

The timely detection of diseases is one of the biggest challenges in guiding consumers and patients to appropriate care, with under-diagnosis, misdiagnosis, and long patient journeys to diagnosis and care, unfortunately, being commonplace. In addition, global healthcare systems are overburdened, with organizations required to meet pressures such as growing and aging populations, emerging comorbidity requiring treatment, and the ongoing pandemic.

Enter Ada Health, a Berlin, Germany-based digital health tech startup that helps to diagnose symptoms and offer treatment advice using an AI-enabled platform. Ada helps shorten time to diagnosis by providing medical guidance that is relevant, actionable, and effective, and will increasingly leverage personalized data insights to support the prediction and prevention of diseases.

What started as a shared idea ten years ago has turned into 20 million symptom assessments. Built by doctors, scientists, industry pioneers, and powered by a 10 million-strong userbase, Ada medical AI simplifies healthcare journeys and helps people take care of themselves.

Now Ada’s consumer app has become the world’s most popular and highest-rated symptom assessment app, with over 23 million assessments completed since its global launch. Ada’s doctor-in-your-pocket-style app uses artificial intelligence to try to diagnose symptoms.

Today, Ada announced it has raised $90 million in Series B funding led by Leaps by Bayer, an investment arm of German pharmaceutical giant Bayer, with participation from Samsung Catalyst Fund, Vitruvian Partners, Inteligo Bank, F4, and Mutschler Ventures. The total undisclosed valuation brings that company’s total funding to around $150 million.

Founded in 2011 by entrepreneurs Dr. Claire Novorol, Martin Hirsch, and Daniel Nathrath, Ada’s core system connects medical knowledge with intelligent technology to help all people actively manage their health and medical professionals to deliver effective care. The company said its app has been downloaded over 11 million times.

“Today’s investment will help bring us closer to our goal of improving healthcare outcomes for more than 1 billion people around the world. We’re proud to have investors on board who truly believe in Ada’s technology and vision of transforming the way people access healthcare,” Daniel Nathrath, CEO and co-founder of Ada Health comments on today’s announcement. “We are thrilled to have Leaps by Bayer as the lead investor particularly as our values are very much aligned with putting science and technology as well as a commitment to medical quality and user-centricity at the heart of everything we do.”

Ada Health Founders